University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
NCT Number: NCT00733239
This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Little Rock, Arkansas, 72205, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
Other names: Cycloserine: Calan, Veralan, Diltiazem: Cardizem, Gabapentin: Neurontin, Isradipine: DynaCirc, Naloxone: Narca, Nifedipine: Adalat, Procardia, Placebo, Saline, Verapamil: Veralan
Time frame: Every Session
Time frame: Every Session
Time frame: Every Session
Time frame: Test Sessions
University of Arkansas
Other
Acronym: OMDD2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04325659
Chemically-Induced Disorders, Mental Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT03969238
Agnosia, Chemically-Induced Disorders
Charlottesville, Virginia, United States
View Trial DetailsNCT04454645
Chemically-Induced Disorders, Infant Development
Newark, Delaware, United States
View Trial DetailsNCT03089983
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Kajang, Selangor, Malaysia
View Trial Details